My Companies
Notification
Account
USFDA approved commercial batch manufacturing for the first product on Spokane Line 3, enabling its planned late-FY27 commercialization and supporting Jubilant’s sterile-injectables CDMO expansion.
Jubilant Pharmova Invests CAD 94.5 Million To Double Ruby-Fill Capacity
Jubilant Pharmova Meets Kela's MK Ventures At Emkay Investor Conference